About
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
Current Value
$1.501 Year Return
Current Value
$1.501 Year Return
Key Details
Market Cap
$44.89M
P/E Ratio
-0.51
1Y Stock Return
-18.72%
1Y Revenue Growth
-31.76%
Dividend Yield
0.00%
Price to Book
1.9
Stock's related to FBIO
The stocks that are correlated to FBIO - Fortress Biotech, Inc. are KN, MLKN, JOBY, WSC, GPRO
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| 34.43% | $1.18B | -15.60% | 0.00% | |
M MLKNMillerKnoll, Inc. | 34.26% | $1.18B | -35.37% | 4.45% |
J JOBYJoby Aviation, Inc. | 32.95% | $4.46B | +15.51% | 0.00% |
| 32.88% | $4.72B | -41.70% | 0.29% | |
G GPROGoPro, Inc. | 32.87% | $86.27M | -74.03% | 0.00% |
| 32.54% | $171.69M | -65.94% | 0.00% | |
T TEXTerex Corp. | 32.43% | $2.38B | -44.42% | 2.00% |
| 31.80% | $1.87B | -21.01% | 0.75% | |
P PLABPhotronics, Inc. | 31.40% | $1.16B | -34.83% | 0.00% |
| 31.39% | $290.67M | -37.93% | 0.00% | |
| 31.16% | $1.93B | -44.90% | 0.00% | |
C CDZICadiz, Inc. | 30.90% | $218.37M | +6.80% | 0.00% |
| 30.81% | $294.92M | -13.18% | 0.00% | |
V VERIVeritone, Inc. | 30.39% | $99.89M | -67.39% | 0.00% |
D DIODDiodes, Inc. | 30.25% | $1.72B | -45.77% | 0.00% |
| 30.23% | $559.11M | -35.29% | 0.00% | |
D DANDana, Inc. | 30.13% | $1.81B | +0.08% | 3.35% |
| 29.98% | $713.23M | -72.41% | 0.00% | |
G GBIOGeneration Bio Co. | 29.84% | $26.64M | -90.14% | 0.00% |
C CTSCTS Corp. | 29.82% | $1.12B | -15.85% | 0.44% |
ETF's related to FBIO
The ETFs that are correlated to FBIO - Fortress Biotech, Inc. are CPRJ, IWC, PBE, ARKG, PBW
Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| 39.52% | $48.65M | 0.69% | |
| 36.92% | $809.63M | 0.6% | |
| 35.17% | $229.13M | 0.58% | |
| 34.94% | $987.53M | 0.75% | |
| 34.78% | $215.17M | 0.65% | |
| 33.66% | $48.48M | 0.5% | |
X XBISPDR Biotech ETF | 33.10% | $5.06B | 0.35% |
| 32.65% | $5.70B | 0.45% | |
| 32.40% | $63.84B | 0.19% | |
| 32.28% | $11.24B | 0.07% | |
| 32.25% | $10.93B | 0.24% | |
| 31.52% | $141.74M | 0.5% | |
| 31.32% | $2.38B | 0.39% | |
| 31.31% | $521.56M | 0.2% | |
| 31.13% | $320.39M | 0.79% | |
P PRNTARK 3D Printing ETF | 30.97% | $73.55M | 0.66% |
| 30.90% | $1.31B | 0.15% | |
| 30.79% | $11.04B | 0.24% | |
| 30.70% | $1.12B | 0.31% | |
| 30.64% | $16.19B | 0.04% | |
News
SeekingAlpha
Fortress Biotech, Inc. (NASDAQ:FBIO) Q4 2024 Earnings Conference Call March 26, 2025 4:30 PM ETCompany ParticipantsJaclyn Jaffe - Senior Director, Corporate...
SeekingAlpha
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.
Finnhub
Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the...
Yahoo
Sentynl took over the therapy’s development and commercialisation from Fortress Biotech's subsidiary Cyprium Therapeutics.
Finnhub
Solana Beach, Ahmedabad, India - Sentynl Therapeutics, Inc. , a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. , and Fortress Biotech, Inc. announced that the U.S....
Yahoo
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium also retains ownership over any Priority Review Voucher that may be issued at NDA approval MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the acceptance for
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
0% Expense Ratios with TLH
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds